<DOC>
	<DOCNO>NCT02798120</DOCNO>
	<brief_summary>This multi-center , open label long-term safety ( LTS ) study conduct approximately 600 subject acne vulgaris .</brief_summary>
	<brief_title>P3 Long Term Safety Study Once Daily SB204 Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Have complete 12 week treatment NIAC301 NIAC302 Terminated early SB204 Phase 3 pivotal study reason Have ongoing adverse event Week 12 visit NIAC301 NIAC302 warrant stop study drug application Have use medication vitamins 12 week immediately precede study report exacerbate acne .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>